Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
P53 AND HER-2 NEU OVEREXPRESSION IN OVARIAN BORDERLINE TUMORS/
Autore:
ELTABBAKH GH; BELINSON JL; KENNEDY AW; BISCOTTI CV; CASEY G; TUBBS RR;
Indirizzi:
ROSWELL PK CANC INST,DEPT GYNECOL ONCOL,ELM & CARLTON ST BUFFALO NY 14263 CLEVELAND CLIN FDN,DEPT GYNECOL CLEVELAND OH 44195 CLEVELAND CLIN FDN,DEPT PATHOL CLEVELAND OH 44195 CLEVELAND CLIN FDN,DEPT CANC BIOL CLEVELAND OH 44195
Titolo Testata:
Gynecologic oncology
fascicolo: 2, volume: 65, anno: 1997,
pagine: 218 - 224
SICI:
0090-8258(1997)65:2<218:PAHNOI>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
SUPPRESSOR PROTEIN P53; STAGE-I CARCINOMAS; ONCOGENE EXPRESSION; GENE-MUTATIONS; BREAST-CANCER; NEU ONCOGENE; C-ERBB-2; NEOPLASMS; AMPLIFICATION; ACTIVATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
47
Recensione:
Indirizzi per estratti:
Citazione:
G.H. Eltabbakh et al., "P53 AND HER-2 NEU OVEREXPRESSION IN OVARIAN BORDERLINE TUMORS/", Gynecologic oncology, 65(2), 1997, pp. 218-224

Abstract

Objective: To study p53 and HER-2/neu expression in borderline ovarian tumors (BLOT) by assessing their frequency, coexpression, and relationship to histologic type, FIGO stage, tumor recurrence, and survival. Methods: Forty-two patients with confirmed BLOT (25 serous, 13 mucinous, and 4 seromucinous) were followed for 1.5 to 14 years (mean, 6.3). Thirty (71%) patients had FIGO stage I and 12 (29%) had FIGO stage III disease. Paraffin-embedded sections from the 42 BLOT, 5 normal ovaries, and 10 benign ovarian cystadenomas were stained using monoclonal antibodies against human p53 (DAKO-p53, DAKO, Denmark) and HER-2/neu (C-erB-2, Triton, Parkway, CA). Positive staining was semiquantitated depending on the number of positively stained tumor cells. p53 and HER-2/neu overexpressions were correlated to each other, to histologic subtype, stage, tumor recurrence, and survival. Results: None of the patients had tumor recurrence. The 5- and 10-year disease-free survival was100%. None of the normal ovaries or ovarian cystadenomas demonstratedoverexpression of p53 or HER-2/neu. Ten (24%) BLOT demonstrated overexpression of p53 and 9 (21%) demonstrated overexpression of HER-2/neu. HER-2/neu overexpression was significantly greater in stage III than in stage I tumors (P = 0.0157). Seromucinous BLOT demonstrated significantly greater p53 overexpression compared with other histologic subtypes (P = 0.030). Coexpression of p53 and HER-2/neu occurred in 4 patients (9.5%). There was no significant correlation between the overexpression of p53 and HER-2/neu (P = 0.180) and no significant relationshipbetween p53 and HER-2/neu overexpression and the presence of microinvasion, ability to perform optimal cytoreductive surgery, tumor recurrence, or survival. Conclusions: p53 and HER-2/neu overexpression occurred in about 20-25% of BLOT overall and more commonly in seromucinous and advanced stage tumors. Coexpression occurred in 9.5% of the cases with no significant correlation between the expression of p53 and HER-2/neu. (C) 1997 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 12:21:34